Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.56 |
| ▸ | LPL | P06858 | 7/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 7/20 | 0.34 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.31 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL520617 | 0.87 | FFAR1 (0.57) | FFAR1LPLLIPGAAK1IRAK4 | |
| SCHEMBL9278209 | 0.85 | FFAR1 (0.59) | FFAR1LPLLIPGAAK1IRAK4 | |
| SCHEMBL19222191 | 0.85 | FFAR1 (0.59) | FFAR1LPLLIPGAAK1IRAK4 | |
| SCHEMBL9286876 | 0.85 | FFAR1 (0.59) | FFAR1LPLLIPGAAK1IRAK4 | |
| SCHEMBL15508014 | 0.85 | FFAR1 (0.58) | FFAR1LPLLIPGAAK1IRAK4 | |
| SCHEMBL17251872 | 0.83 | FFAR1 (0.54) | FFAR1LPLLIPGF11 | |
| SCHEMBL2511129 | 0.83 | FFAR1 (0.60) | FFAR1LPLLIPGIRAK4F11 | |
| SCHEMBL23540269 | 0.83 | FFAR1 (0.53) | FFAR1LPLLIPGIRAK4 | |
| SCHEMBL15885039 | 0.82 | FFAR1 (0.56) | FFAR1LPLLIPGAAK1F11 | |
| SCHEMBL1331340 | 0.81 | FFAR1 (0.61) | FFAR1LPLLIPGIRAK4F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240182460-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PETRA PHARMA CORPORATION | 2024-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240182460-A1 | ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE | PIK3CA, PIK3R4, PIK3R5 | FFAR1 367/4885LPL 1668/4885LIPG 1771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.